Day 1: mAb’s, CAR-T, and Checkpoints . . . oh my!

| Jack Aiello

Oh my indeed, what a very long but exciting day at ASH. It began with a 7:30 a.m. working breakfast of the IMF’s International Myeloma Working Group (IMWG) that consists of more than 200 myeloma experts from around the world (including 17 new members in 2016). One of their tasks is to write consensus guidelines and […]

MRD measurement and BSRI are bringing us closer to cure

| Jim Omel

Patients understand that improved treatment for myeloma can result in unprecedented depth of response, and myeloma treatment has changed dramatically in the last few years. Prior to 1997 when I was diagnosed, complete response (CR) was defined as a 75% reduction in M-protein. Stringent CR (sCR) did not exist because this deep level of control […]